Navigation Links
Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
Date:11/4/2013

INDIANAPOLIS, Nov. 4, 2013 /PRNewswire/ -- Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A., (IBA).

The purchase of IBA's Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses.

In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a new, state of the art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. A location is expected to be determined by the end of 2013.

"This is just the beginning," said John Zehner, Executive Vice President and Chief Operating Officer, Zevacor Molecular. "With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics."

The main focus of the first 70 MeV Cyclotron will be the commercial manufacture of Strontium 82 to ensure ample, stable United States based supply of Strontium 82/Rubidium 82 generators for use in the diagnosis of cardiovascular disease.  This important radiotracer has no current commercial supplier, and only has United States and foreign based supply from national labs.

Although the primary focus is the manufacture of Strontium 82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 

"We are delighted that Zevacor Molecular selected IBA to install the first commercial 70 MeV Cyclotron dedicated to the production of radiopharmaceuticals in the United States," said Olivier Legrain, Chief Executive Officer, IBA. "We are honored to partner with Zevacor Molecular and participate in their mission to help advance the care of patients through the provision of advanced diagnostic agents."

About Zevacor Molecular
Zevacor Molecular was established in 2012.  Their efforts come at a time when there is little certainty of supply in the market for medical isotopes. The 70 MeV will have the ability to supply patients with medically necessary isotopes used for diagnostic imaging and therapies within oncology, neurology and cardiology. This also opens up several research isotopes currently not widely available in the United States. More information can be found at www.zevacor.com

About IBA
Ion Beam Applications S.A., (IBA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment.  IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions.  IBA also focuses on the development and supply of dosimetry solutions for quality assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications. More information can be found at www.iba-worldwide.com


'/>"/>
SOURCE Zevacor Molecular
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zevacor Molecular to Open Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
2. PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors
3. LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING
4. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
5. MR Solutions to Launch Two World Firsts in Pre Clinical Scanning at the World Molecular Imaging Conference in Savannah This Week - a Combined 3T, Cryogen Free MRI/PET and a 3T MRI/SPECT
6. Technology Innovation Provides Catalyst for Scientific Breakthroughs in Precision Medicine at World Molecular Imaging Congress
7. World Molecular Imaging Congress to Feature Scientific Breakthroughs in Molecular Multimodal Imaging Essential to Precision Medicine
8. Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists
9. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
10. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
11. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):